Emsam (selegiline transdermal system) is the trade name of an antidepressant of the monoamine oxidase inhibitor (MAOI) class. Emsam is a transdermal patch containing the MAOI selegiline. Selegiline, in small doses, is most commonly used in the treatment of Parkinson's disease. It is also effective in higher doses for the treatment of major depressive disorder. On February 28, 2006 the U.S. Food and Drug Administration (FDA) approved EMSAM for the treatment of major depression.
Read more about Emsam: Inception and Development, Emsam Advantages, Usage, Medication Interactions, Name Origin, Manufacturer and Distributor